Liquid Biopsy Market By Product Type (Reagents & Kits and Equipment), By Sample (Cell Free DNA, Circulating Tumor Cells, and Exosomes), By Application (Oncology Testing, Non-Invasive Prenatal Testing, and Transplant Care), By End User (Hospitals, Research Laboratories, Diagnostic Laboratories, and Patients) and By Region, Trends, Analysis and Forecast till 2030

Liquid Biopsy Market accounted for USD 1.32 Billion in 2020 and is estimated to be USD 7.92 Billion by 2030 and is anticipated to register a CAGR of 19.8%.

Liquid biopsy is a non-invasive alternative to surgical biopsies, which enables healthcare practitioners to collect information regarding tumor through a simple blood sample. A liquid biopsy test can detect epidermal growth factor receptor (EGFR) gene mutations, which occur in patients suffering from non-small cell lung cancer. Liquid biopsy traces tumor DNA in the blood sample, which can aid in selecting treatment for a particular patient. These biopsies are majorly conducted for identification of lung, breast, and prostate cancer.

The world is one of the major factors driving growth of the liquid biopsy market, as liquid biopsies are non-invasive and require only 5 milliliters of blood for performing detection test. Furthermore, liquid biopsy offer advantages such as tolerability and convenience to detect disease progression or treatment resistance before clinical symptoms appear. Liquid biopsies detect genetic changes more effectively as compared to conventional tissue biopsy.  Moreover, the test also detects risks of developing chromosomal abnormalities such as Edwards’s syndrome, Down syndrome, and X and Y chromosome abnormalities, which in turn is fueling market growth. However, variability of results interpretation due to sensitivity of biopsy may restrain growth of the market.

Generally, there has be increase in the population number of people who have cancer disease. Cancer is the second leading death causes in world. Liquid biopsy have many benefits of cancer daignostics process that are – therapy monitoring, patient comfort, and tumor heterogeneity. the sevral factors that attributed to cancer such as infectious agents ( Hepatitis B and C) , tobacco consumption and environmental factors .

The liquid Biopsy market is segmented based on product, sample, application, end user and region.

On the basis of sample, the liquid biopsy market is segmented into Cell free DNA, Circulating Tumor cell and Exosomes. Based on products the target market is segmented into Reagents & kits and Equipment’s. On the basis of application, the target market is segmented into oncology testing, Non-invasive prenatal testing and Transplant care. On the basis of end user the target market is segmented into hospitals, Research laboratories, diagnostic Laboratories and patients. On the basis of region, the market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa.

Regional Insights:                                            

The liquid biopsy market accounted for USD 1.32 billion in 2020 and is estimated to be USD 7.92 billion by 2030 and is anticipated to register a CAGR of 19.8%. On region the liquid biopsy market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to lead the market and estimate for about 35% revenue share in 2020. As North America is the leading liquid market and have highly well-developed system such as healthcare in US and Canada.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at , regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2020 to 2030. For the purpose of this study, has segmented the liquid biopsy market report based on product, sample, End User, application, and region.    

Liquid Biopsy Market, By Region:

• North America
  • Middle East & Africa
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia Pacific
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • U.S.
  • Canada

Key players operating in the liquid biopsy market include Illumina, Inc., Roche AG, Natera, Inc., Laboratory Corporation of America Holdings (LabCorp), Qiagen N.V., Thermo Fisher Scientific Inc., Exact Sciences Corp., Biocept, Inc., Genomic Health, Inc., Guardant Health, TrovaGene Inc., CareDx Inc., Adaptive Biotechnologies Corporation, and Biocartis SA.

• Illumina
• Roche AG, Natera, Inc
• Laboratory Corporation of America Holdings (LabCorp)
• Qiagen N.V
•  Thermo Fisher Scientific Inc
• Exact Sciences Corp
•  Biocept, Inc
• Genomic Health Inc.
•  Guardant Health
• TrovaGene Inc
• CareDx Inc
• Adaptive Biotechnologies Corporation
• Biocartis SA.